Original title: Transcatheter Aortic Valve Implantation for Pure Severe Native Aortic Valve Regurgitation. Reference: David A. Roy et al. J Am Coll Cardiol 2013. Article in press. Percutaneous aortic valve replacement (TAVI) has become a standard treatment for patients with severe aortic stenosis and a high surgical risk. However for those patients who have pure aortic insufficiency, (failure...
Original title: 5-Year Outcome After Aortic Valve Implantation Reference: Stefan Toggweiler, et al. J Am Coll Cardiol 2013;61:413–9 Percutaneous aortic valve implantation (TAVI) is now a valid strategy as we know its short and medium term evolution but we do not have enough information available about the long term. The aim of this study was to analyze the...
Original title: Impact of Post-Procedural Aortic Regurgitation on Mortality Alter Trancatheter Aortic Valve Implantation Reference: Kentaro Hayashida, et al. J Am Coll Interv 2012;5:1247-56 Transcatheter aortic valve implantation (TAVI) sprung up as a valid strategy to treat patients with severe high risk AS (aortic stenosis). However, residual aortic regurgitation (post AR) and post-dilation remain unsolved. Between October 2006...
Original title: Valve-in-Valve Implantation of Medtronic CoreValve Prosthesis in Patients with Failing Bioprosthetic Aortic Valves. Reference: Axel Linke el al. Circ Cardiovasc Interv. 2012;5:689-697. This study evaluates the safety, feasibility and results of Core Valve implants on patients with bioprostheses dysfunctional by stenosis, insufficiency or a combination of both. Biological prostheses are preferred over mechanical ones for patients...
Reference: Durand E. et al (JACC CV interventions 2012 in press)1 When percutaneous aortic valve replacement (AVR) first began the procedure required a large-bore sheath (22-24 F), being the most frequent surgical strategy when using general anesthesia. Continuous technological advances achieved the miniaturization of devices which allow the procedure to be performed with a much...